Post-essential Thrombocythemia Myelofibrosis
📧 Sign up to get email alerts when something new happens for Post-essential Thrombocythemia Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis [Phase 2]
This update describes a Phase 2 study evaluating momelotinib in combination with luspatercept for transfusion-dependent myelofibrosis; the t…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Extended Access of Momelotinib in Adults With Myelofibrosis [Phase 2]
This clinical trial update notes extended-access use of momelotinib in adults with myelofibrosis, including primary myelofibrosis and relate…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) [Phase 3]
This Phase 3 trial evaluates pelabresib in combination with ruxolitinib for myelofibrosis and is currently recruiting across primary MF and …
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) [Phase 3]
Phase 3 study of bomedemstat (MK-3543-017) sponsored by Merck is currently recruiting to evaluate safety and efficacy in essential thrombocy…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis [Phase 1]
Phase 1 study evaluating pelabresib added to ruxolitinib in Japanese adults with myelofibrosis (primary, post-polycythemia vera, or post-ess…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms [Phase 1]
An update on a Phase 1 safety and tolerability study of INCB057643 in myelofibrosis and other advanced myeloid neoplasms, with the trial cur…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Registry Platform Myelofibrosis and Anemia
A ClinicalTrials.gov registry entry for a recruiting trial by iOMEDICO AG focused on myelofibrosis and anemia. It lists several MF-related c…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) [Phase 1]
Phase 1 study of AJ1-11095 in patients with primary myelofibrosis and post-polycythemia vera or post-essential thrombocythemia myelofibrosis…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias [Phase 2]
This clinical trial update announces a Phase 2 study evaluating selinexor and pacritinib in JAK inhibitor‑naïve myelofibrosis patients with …
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) [Phase 1, Phase 2]
An open-label Phase 1/2 study evaluating tasquinimod in primary myelofibrosis and myelofibrosis following PV or essential thrombocythemia is…
-
CLINICAL_TRIALS other · 2026-01-07Clinical Trial Update: Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) [Phase 2]
This is a Phase 2 clinical trial evaluating reparixin in patients with myelofibrosis and related myeloproliferative neoplasms; the study is …
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes fedratinib in Japanese patients with DIPSS-intermediate/high-risk primary myelofibrosis, post-po…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib [Phase 3]
Phase 3 trial evaluating navtemadlin added to ruxolitinib in JAK inhibitor-naïve myelofibrosis patients with suboptimal response; currently …
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]
This update reports on a completed Phase 1/2 study evaluating the safety, pharmacokinetics, pharmacodynamics, and dose expansion of PXS-5505…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis [Phase 2]
A Phase 2 clinical trial evaluating a combination of Ropeginterferon alfa-2b and ruxolitinib for myelofibrosis is currently recruiting, incl…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis [Phase 2]
A Phase 2 trial comparing NS-018 to best available therapy in myelofibrosis was terminated, and results have been posted on May 23, 2025.
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis [Phase 2]
Phase II trial update for Flonoltinib maleate tablets in intermediate-high-risk myelofibrosis; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2024-11-06Clinical Trial Update: A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
A post-marketing surveillance study to assess the safety of fedratinib in Korean patients with myelofibrosis, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) [Phase 3]
Phase 3 MANIFEST-2 study of pelabresib (CPI-0610) in myelofibrosis has posted results as of Oct 28, 2024; the trial remains active but not r…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors [Phase 2]
A Phase 2 trial of selinexor in patients with myelofibrosis refractory or intolerant to JAK1/2 inhibitors was terminated, with results poste…
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) [Phase 3]
A Phase 3 trial (LIMBER-313) evaluating Parsaclisib in combination with Ruxolitinib for myelofibrosis was terminated, with results posted in…
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) [Phase 3]
Phase 3 LIMBER-304 trial evaluating parsaclisib with ruxolitinib in myelofibrosis patients with suboptimal response to ruxolitinib was termi…
-
FDA approval · 2024-07-30FDA Approved: INREBIC — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for INREBIC (fedratinib hydrochloride) from Celgene Corporation (NDA 212327).
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition [Phase 1]
A Phase 1 clinical trial at Fox Chase Cancer Center tests the combination of pacritinib and talazoparib in myeloproliferative neoplasms unre…
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib [Phase 3]
A Phase 3 trial evaluating fedratinib versus best available therapy in high- or intermediate-risk myelofibrosis subtypes after ruxolitinib f…